Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Identification and characterization of immunoregulatory ILC3s for use as a tolerogenic cell therapy
FY 2023-24
Summary
Adoptive cell therapy (ACT) is a treatment in which immune cells are expanded and enhanced within a lab, and then infused into the patient to treat their disease. It has revolutionized the treatment of various diseases, and holds the same therapeutic potential for autoimmune diseases and transplantation rejection. Group 3 innate lymphoid cells (ILC3s) are important cells of the immune system that are able to regulate inflammation and maintain tissue health. They have been associated with more favourable outcomes in graft-versus-host disease (GVHD), which is a common side effect of transplantation in which donor cells attack recipient cells, resulting in multi-organ damage. Ongoing work within our lab has shown that ACT of ILC3s protects mice from clinical signs of GVHD, but the mechanism remains unknown. However, ILC3s consist of functionally distinct subsets, and this diversity contributes to contradictory reports of whether they play protective or harmful roles within diseases. Therefore, in this research grant, I propose that the isolation of distinct ILC3 subsets and identification of the cells mediating the observed protective features in the GVHD mouse model can serve as a novel, regulatory cell therapy. Currently approved treatments for diseases related to autoimmunity, inflammation and transplantation rejection involve use of broadly suppressive drugs that leave patients vulnerable to infections and severe side effects. Thus, there is a desperate need for tolerizing therapies that are more precise and effective. These initial studies will allow us to identify mechanistic actions of adoptively transferred immunoprotective ILC3s, and are key first steps in harnessing the regulatory, therapeutic power of these cells.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506366
Name
Nault Hayley
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification and characterization of immunoregulatory ILC3s for use as a tolerogenic cell therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive Cell Therapy; Autoimmunity; Cell Engineering; Graft Versus Host Disease; Immunology; Immunosuppression; Immunotherapy; Innate Lymphoid Cells; Regulatory Immune Cells; Transplantation
Abstract
Adoptive cell therapy (ACT) is a treatment in which immune cells are expanded and enhanced within a lab, and then infused into the patient to treat their disease. It has revolutionized the treatment of various diseases, and holds the same therapeutic potential for autoimmune diseases and transplantation rejection. Group 3 innate lymphoid cells (ILC3s) are important cells of the immune system that are able to regulate inflammation and maintain tissue health. They have been associated with more favourable outcomes in graft-versus-host disease (GVHD), which is a common side effect of transplantation in which donor cells attack recipient cells, resulting in multi-organ damage. Ongoing work within our lab has shown that ACT of ILC3s protects mice from clinical signs of GVHD, but the mechanism remains unknown. However, ILC3s consist of functionally distinct subsets, and this diversity contributes to contradictory reports of whether they play protective or harmful roles within diseases. Therefore, in this research grant, I propose that the isolation of distinct ILC3 subsets and identification of the cells mediating the observed protective features in the GVHD mouse model can serve as a novel, regulatory cell therapy. Currently approved treatments for diseases related to autoimmunity, inflammation and transplantation rejection involve use of broadly suppressive drugs that leave patients vulnerable to infections and severe side effects. Thus, there is a desperate need for tolerizing therapies that are more precise and effective. These initial studies will allow us to identify mechanistic actions of adoptively transferred immunoprotective ILC3s, and are key first steps in harnessing the regulatory, therapeutic power of these cells.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nault, Hayley
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~